{"active":true,"archived":false,"automaticallyActive":true,"closed":false,"commentCount":2,"competitive":0.9497578117580017,"createdAt":"2026-01-11T18:01:54.338474Z","creationDate":"2026-01-12T23:09:01.744065Z","cyom":false,"deploying":false,"description":"Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more.\n\nThis market will resolve to \"Yes\" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to \"No.\"\n\nAn approval is defined as:\nFor new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)\nFor already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced\nFor generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)\nFor biosimilars: FDA approval of a 351(k) application\n\nThe following constitute qualifying approvals:\nStandard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs\n\nThe following do not constitute qualifying approvals:\nApprovable letters that require additional actions before approval\nTentative approvals pending patent or exclusivity expiration\nFDA requests for additional information or studies\nExtension of Prescription Drug User Fee Amendments dates\nApproval for compassionate use or expanded access programs only\nApproval only for export or for use outside the United States\nEmergency Use Authorization (EUA) without full approval\nComplete Response Letters (CRLs) indicating the application cannot be approved in its current form\n\nIf the listed drug is approved within this market’s timeframe, the market will resolve to \"Yes,\" regardless of potential Advisory Committee votes against approval or later withdrawal of approval.\n\nConditional approvals may include post-marketing requirements or commitments and still qualify.\n\nThe primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.","enableNegRisk":false,"enableOrderBook":true,"endDate":"2026-12-31T00:00:00Z","featured":false,"icon":"https://polymarket-upload.s3.us-east-2.amazonaws.com/fda-approves-mercks-clesrovimab-infant-rsv-prevention-mk1654-UwIlSPqRRYN3.jpg","id":"158107","image":"https://polymarket-upload.s3.us-east-2.amazonaws.com/fda-approves-mercks-clesrovimab-infant-rsv-prevention-mk1654-UwIlSPqRRYN3.jpg","liquidity":3011.4458,"liquidityClob":3011.4458,"markets":[{"acceptingOrders":true,"acceptingOrdersTimestamp":"2026-01-12T23:07:19Z","active":true,"approved":true,"archived":false,"automaticallyActive":true,"bestAsk":0.28,"bestBid":0.26,"clearBookOnStart":true,"clobRewards":[{"assetAddress":"0x2791Bca1f2de4661ED88A30C99A7a9449Aa84174","conditionId":"0xa9e844555c3aeac59e6104f266bee4ce930b6941fbea4053eb1ab440cdc4ea8e","endDate":"2500-12-31","id":"55010","rewardsAmount":0,"rewardsDailyRate":2,"startDate":"2026-01-13"}],"clobTokenIds":"[\"37046612607917670308080402239015003453544974634272162340833828461002861888000\", \"88804198326803208210051239842322035314858564707784139836567124873063625803223\"]","closed":false,"competitive":0.9497578117580017,"conditionId":"0xa9e844555c3aeac59e6104f266bee4ce930b6941fbea4053eb1ab440cdc4ea8e","createdAt":"2026-01-11T18:01:55.248991Z","customLiveness":0,"cyom":false,"deploying":false,"deployingTimestamp":"2026-01-12T22:52:16.73248Z","description":"Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more.\n\nThis market will resolve to \"Yes\" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to \"No.\"\n\nAn approval is defined as:\nFor new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)\nFor already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced\nFor generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)\nFor biosimilars: FDA approval of a 351(k) application\n\nThe following constitute qualifying approvals:\nStandard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs\n\nThe following do not constitute qualifying approvals:\nApprovable letters that require additional actions before approval\nTentative approvals pending patent or exclusivity expiration\nFDA requests for additional information or studies\nExtension of Prescription Drug User Fee Amendments dates\nApproval for compassionate use or expanded access programs only\nApproval only for export or for use outside the United States\nEmergency Use Authorization (EUA) without full approval\nComplete Response Letters (CRLs) indicating the application cannot be approved in its current form\n\nIf the listed drug is approved within this market’s timeframe, the market will resolve to \"Yes,\" regardless of potential Advisory Committee votes against approval or later withdrawal of approval.\n\nConditional approvals may include post-marketing requirements or commitments and still qualify.\n\nThe primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.","enableOrderBook":true,"endDate":"2026-12-31T00:00:00Z","endDateIso":"2026-12-31","featured":false,"feesEnabled":false,"funded":false,"groupItemThreshold":"0","groupItemTitle":"","hasReviewedDates":true,"holdingRewardsEnabled":false,"icon":"https://polymarket-upload.s3.us-east-2.amazonaws.com/fda-approves-mercks-clesrovimab-infant-rsv-prevention-mk1654-UwIlSPqRRYN3.jpg","id":"1162139","image":"https://polymarket-upload.s3.us-east-2.amazonaws.com/fda-approves-mercks-clesrovimab-infant-rsv-prevention-mk1654-UwIlSPqRRYN3.jpg","lastTradePrice":0.27,"liquidity":"3011.4458","liquidityClob":3011.4458,"liquidityNum":3011.4458,"manualActivation":false,"marketMakerAddress":"","negRisk":false,"negRiskOther":false,"negRiskRequestID":"","new":false,"oneDayPriceChange":-0.02,"oneWeekPriceChange":0.07,"orderMinSize":5,"orderPriceMinTickSize":0.01,"outcomePrices":"[\"0.27\", \"0.73\"]","outcomes":"[\"Yes\", \"No\"]","pagerDutyNotificationEnabled":false,"pendingDeployment":false,"question":"FDA approves Retatrutide this year?","questionID":"0x28ca6aea72aab17e940ef2cd33fe2b8b75be387cd6a6f8a5652f3789b121aa71","ready":false,"requiresTranslation":false,"resolutionSource":"","resolvedBy":"0x65070BE91477460D8A7AeEb94ef92fe056C2f2A7","restricted":true,"rewardsMaxSpread":3.5,"rewardsMinSize":100,"rfqEnabled":false,"slug":"fda-approves-retatrutide-this-year","spread":0.02,"startDate":"2026-01-12T23:07:41.222409Z","startDateIso":"2026-01-12","submitted_by":"0x91430CaD2d3975766499717fA0D66A78D814E5c5","umaBond":"500","umaResolutionStatuses":"[]","umaReward":"5","updatedAt":"2026-02-11T01:23:05.334948Z","volume":"383839.304177","volume1mo":383839.3041769989,"volume1moClob":383839.3041769989,"volume1wk":32174.525671,"volume1wkClob":32174.525671,"volume1yr":383839.3041769989,"volume1yrClob":383839.3041769989,"volume24hr":1.45,"volume24hrClob":1.45,"volumeClob":383839.304177,"volumeNum":383839.304177}],"negRiskAugmented":false,"new":false,"openInterest":0,"pendingDeployment":false,"requiresTranslation":false,"resolutionSource":"","restricted":true,"showAllOutcomes":true,"showMarketImages":true,"slug":"fda-approves-retatrutide-this-year","startDate":"2026-01-12T23:09:01.744068Z","tags":[{"createdAt":"2024-11-11T18:32:53.640553Z","id":"101221","label":"drug","requiresTranslation":false,"slug":"drug","updatedAt":"2026-02-06T20:03:11.687201Z"},{"createdAt":"2026-01-11T18:01:54.734515Z","id":"103116","label":"GLP","requiresTranslation":false,"slug":"glp","updatedAt":"2026-02-06T19:58:13.311696Z"},{"createdAt":"2026-01-11T18:01:54.897124Z","id":"103118","label":"Eli Lilly","requiresTranslation":false,"slug":"eli-lilly","updatedAt":"2026-02-06T20:03:51.921207Z"},{"createdAt":"2023-11-02T21:16:20.826Z","forceHide":true,"forceShow":false,"id":"74","label":"Science","publishedAt":"2023-11-02 21:16:20.623+00","requiresTranslation":false,"slug":"science","updatedAt":"2026-02-06T20:15:20.36977Z","updatedBy":13},{"createdAt":"2026-01-11T18:01:54.746493Z","id":"103117","label":"Chinese Peptides","requiresTranslation":false,"slug":"chinese-peptides","updatedAt":"2026-02-06T20:17:30.730561Z"},{"createdAt":"2024-02-21T23:06:12.324Z","forceShow":false,"id":"1401","label":"Tech","publishedAt":"2024-02-21 23:06:12.305+00","requiresTranslation":false,"slug":"tech","updatedAt":"2026-02-06T20:17:30.722289Z"},{"createdAt":"2024-12-13T19:40:18.578389Z","id":"101489","label":"FDA","requiresTranslation":false,"slug":"fda","updatedAt":"2026-02-06T20:07:42.292472Z"}],"ticker":"fda-approves-retatrutide-this-year","title":"FDA approves Retatrutide this year?","updatedAt":"2026-02-11T01:23:46.605854Z","volume":383839.304177,"volume1mo":383839.3041769989,"volume1wk":32174.525671,"volume1yr":383839.3041769989,"volume24hr":1.45}